Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

Aurobindo Pharma will manufacture and supply these injectable HIV treatment across 133 countries, including several low and ...

Aurobindo Pharma to manufacture and supply long-acting injectable HIV treatment in 133 countries, offering alternative to ...

We’ve come a long way in treating HIV, the virus that can lead to AIDs. Just last month, the FDA approved a medication that ...

Aurobindo Pharma will manufacture & supply long-acting injectable HIV treatment cabotegravir across 133 countries, including ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) ...